MedTrace Logo

A Drug-Drug Interaction Study of Digoxin and PA21

NCT01477411 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2012-01-18

No results posted yet for this study

Summary

The purpose of this study is to determine if Digoxin is affected by PA21.

Conditions

  • Drug Interaction Potentiation

Interventions

DRUG

PA21

The maximum dose of PA21 will be 15.0 g/day.

DRUG

Digoxin

The maximum dosage of Digoxin will be 0.5 mg/day

Sponsors & Collaborators

  • Vifor Pharma

    lead INDUSTRY

Principal Investigators

  • Peter Winkle, MD · ACRI - Phase 1 (Advanced Clinical Research Institute)

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2012-01-31
Completion
2012-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01477411 on ClinicalTrials.gov